Grant R Wilkinson
Overview
Explore the profile of Grant R Wilkinson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1707
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monteiro J, Hiti E, Hardy E, Wilkinson G, Gorden J, Gorden A, et al.
Chem Commun (Camb)
. 2021 Feb;
57(20):2551-2554.
PMID: 33585852
A new naphthylsalophen and its 3 : 2 ligand-to-lanthanide sandwich-type complexes were isolated. When excited at 380 nm, the complexes display the characteristic metal-centred emission for Nd, Er and Yb....
2.
Stollings J, Thompson J, Ferrell B, Scheinin M, Wilkinson G, Hughes C, et al.
Ann Pharmacother
. 2018 Jan;
52(6):513-521.
PMID: 29363356
Background: The relationship between plasma concentration of sedatives and delirium is unknown. Objective: We hypothesized that higher plasma concentrations of lorazepam are associated with increased delirium risk, whereas higher plasma...
3.
Haas D, Gebretsadik T, Mayo G, Menon U, Acosta E, Shintani A, et al.
J Infect Dis
. 2009 Feb;
199(6):872-80.
PMID: 19239339
Background: Polymorphisms in CYP2B6 affect the steady-state plasma concentrations of nevirapine and efavirenz. In many resource-limited countries, a single dose of nevirapine has been widely prescribed to pregnant women at...
4.
Kurnik D, Sofowora G, Donahue J, Nair U, Wilkinson G, Wood A, et al.
Anesthesiology
. 2008 Nov;
109(6):1092-9.
PMID: 19034106
Background: Loperamide, a potent opioid, has been used as an in vivo probe to assess P-glycoprotein activity at the blood-brain barrier, because P-glycoprotein inhibition allows loperamide to cross the blood-brain...
5.
Masica A, Girard T, Wilkinson G, Thomason J, Pun B, Nair U, et al.
Am J Geriatr Pharmacother
. 2007 Nov;
5(3):218-31.
PMID: 17996661
Background: It is unclear how best to measure sedative/analgesic drug exposure in the clinical care of critically ill patients. Large doses and prolonged use of sedatives and analgesics in the...
6.
Motsinger A, Ritchie M, Shafer R, Robbins G, Morse G, Labbe L, et al.
Pharmacogenet Genomics
. 2006 Oct;
16(11):837-45.
PMID: 17047492
Objective: For the HIV-1 reverse transcriptase inhibitor efavirenz, variant drug transporter gene ABCB1 may predict virologic response but not plasma efavirenz exposure. Conversely, variant drug metabolizing enzyme gene CYP2B6 predicts...
7.
Kurnik D, Wood A, Wilkinson G
Clin Pharmacol Ther
. 2006 Sep;
80(3):228-34.
PMID: 16952489
Background: The erythromycin breath test (ERBT) has been widely used as a phenotypic measure of cytochrome P450 (CYP) 3A activity in individuals, as well as its modulation by inhibitors or...
8.
Haas D, Bartlett J, Andersen J, Sanne I, Wilkinson G, Hinkle J, et al.
Clin Infect Dis
. 2006 Aug;
43(6):783-6.
PMID: 16912957
Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity. Among participants in a...
9.
Choo E, Kurnik D, Muszkat M, Ohkubo T, Shay S, Higginbotham J, et al.
J Pharmacol Exp Ther
. 2006 Mar;
317(3):1012-8.
PMID: 16537797
A major functional component of the blood-brain barrier is P-glycoprotein. In principle, inhibition of this efflux transporter would permit greater distribution of its substrates into the brain and increased central...
10.
Takahashi H, Wilkinson G, Nutescu E, Morita T, Ritchie M, Scordo M, et al.
Pharmacogenet Genomics
. 2006 Jan;
16(2):101-10.
PMID: 16424822
Objective: To investigate pharmacokinetic and pharmacodynamic factors associated with population differences in warfarin doses needed to achieve anticoagulation, in particular the possible involvement of genetic variability in vitamin K epoxide...